Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity von Awada, Ahmad, Dumez, Herlinde, Aftimos, Philippe G., Costermans, Jo, Bartholomeus, Sylvie, Forceville, Kathleen, Berghmans, Thierry, Meeus, Marie-Anne, Cescutti, Jessica, Munzert, Gerd, Pilz, Korinna, Liu, Dan, Schöffski, Patrick

Volltext

A phase I dose-finding and pharmacokinetics study of CPC634 (nanoparticle entrapped docetaxel) in patients with advanced solid tumors von Atrafi, Florence, Dumez, Herlinde, Mathijssen, Ron H.J., Menke, Catharina Wilhelmina, Costermans, Jo, Rijcken, Cristianne J.F., Hanssen, Rob, Eskens, Ferry, Schoffski, Patrick

Volltext

Phase I first-in-man trial of a novel bromodomain and extra-terminal domain (BET) inhibitor (BI 894999) in patients (Pts) with advanced solid tumors von Aftimos, Philippe Georges, Bechter, Oliver, Awada, Ahmad, Jungels, Christiane, Dumez, Herlinde, Huyvaert, Nathalie, Costermans, Jo, Lee, Chooi, Meeus, Marie-Anne, Burkard, Ute, Musa, Hanny, Zhao, Yihua, Schoffski, Patrick

Volltext

Phase I safety and pharmacokinetic (PK) dose escalation study with SAR245408 (S) polymorph E, a PI3K inhibitor, in patients (pts) with solid tumors or lymphoma von Bechter, Oliver Edgar, Dumez, Herlinde, Costermans, Jo, Punie, Kevin, Liu, Li, Jiang, Jason, Dedieu, Jean-François, Schöffski, Patrick

Volltext

A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors von Schöffski, Patrick, Aftimos, Philippe, Dumez, Herlinde, Deleporte, Amélie, De Block, Katrien, Costermans, Jo, Billiet, Maureen, Meeus, Marie-Anne, Lee, Chooi, Schnell, David, Goeldner, Rainer-Georg, Awada, Ahmad

Volltext

Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or l... von Bechter, Oliver, Dumez, Herlinde, Costermans, Jo, Punie, Kevin, Hsu, Karl, Dedieu, Jean-François, Ghuysen, Anne-Frédérique, Francesconi, Elisa, Sharma, Jyoti, Liu, Li, Schöffski, Patrick

Volltext

A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors von Schöffski, Patrick, Aftimos, Philippe, Dumez, Herlinde, Deleporte, Amélie, De Block, Katrien, Costermans, Jo, Billiet, Maureen, Meeus, Marie-Anne, Lee, Chooi, Schnell, David, Goeldner, Rainer-Georg, Awada, Ahmad

Volltext

Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or l... von Bechter, Oliver E., Dumez, Herlinde, Costermans, Jo, Punie, Kevin, Hsu, Karl, Dedieu, Jean-François, Ghuysen, Anne-Frédérique, Francesconi, Elisa, Sharma, Jyoti, Liu, Li, Schöffski, Patrick

Volltext

Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity von Awada, Ahmad, Dumez, Herlinde, Aftimos, Philippe G, Costermans, Jo, Bartholomeus, Sylvie, Forceville, Kathleen, Berghmans, Thierry, Meeus, Marie-Anne, Cescutti, Jessica, Munzert, Gerd, Pilz, Korinna, Liu, Dan, Schöffski, Patrick

Volltext

Abstract B281: Phase I study of two dosing schedules of BI 847325, an orally administered dual inhibitor of MEK and aurora kinase B, in patients with advanced solid tumors von Aftimos, Philippe, Dumez, Herlinde, Awada, Ahmad, Billiet, Maureen, Deleporte, Amélie, De Block, Katrien, Costermans, Jo, Meeus, Marie-Anne, Goeldner, Rainer-Georg, Schnell, David, Lee, Chooi, Schöffski, Patrick

Volltext

Phase I trial of volasertib (BI 6727), a polo-like kinase 1 (Plk1) inhibitor, in combination with cisplatin or carboplatin in patients with advanced solid tumors von Schöffski, Patrick, Dumez, Herlinde, Costermans, Jo

Volltext